Tech Company Financing Transactions

Myosana Therapeutics Funding Round

CureDuchenne Ventures, private investors and Muscular Dystrophy Association invested in a $5 million Seed funding round for Myosana Therapeutics. The round was recorded on 1/25/2023.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2617 Nw 59th St. 102
Seattle, WA 98107
USA

Phone

Undisclosed

Website

www.myosanatherapeutics.com

Email Address

Not Recorded

Overview

Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure to improve the quality of life, increase longevity and reduce the disease burden of Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Stan Froehner

        

Chief Executive Officer

Steve Runnels

        

Chief Scientific Officer

Nick Whitehead

        

VP - R & D

Min Kim

        

Browse more venture capital transactions:

Prev: 1/25/2023: Emperia venture capital transaction
Next: 1/25/2023: Angle Health venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary